SL

Sophia Lee

Medical & Health Editor

MedicinePublic HealthPharmaceuticalsEvidence-Based Wellness

Medical editor with MD (University of the Philippines) and 8 years clinical practice before transitioning to health journalism. Covers pharmaceutical developments, public health policy, and evidence-based wellness. Every health claim on her articles is cross-checked against peer-reviewed journals.

Recent articles

World Health Day 2026: WHO Calls World to Stand with Science

World Health Day April 7, 2026. WHO theme: Together for Health, Stand with Science. One Health Summit in Lyon, 800+ scientific institutions gather.

health

Foundayo FDA Approval: Eli Lilly's GLP-1 Pill — Price, Efficacy, vs Wegovy

FDA approves Foundayo (orforglipron) — Eli Lilly's once-daily GLP-1 weight loss pill with no food restrictions. $149/month, 12.4% weight loss, approved in record 50 days.

health

Cold Plunge 2026: The Ice Bath Recovery Revolution Explained

Cold plunge therapy boosts dopamine 250% and cuts inflammation 33% — the #1 recovery trend of 2026. Science, protocols, and why 8M Americans do it weekly.

health

Sober Curious 2026: The Alcohol-Free Generation is Here

The sober curious movement has grown 300% since 2018. 73% of participants are Gen Z and Millennials reshaping health culture and a $457B market.

health

ADHD Brains Fall Asleep While Awake — 2026 Research Shock

Monash University found ADHD brains experience sleep-like slow-wave episodes during waking tasks in up to 30% of study participants — finally explaining attention lapses and focus failures.

health

Meningitis Outbreak Sparks Emergency at University of Kent

University of Kent in Canterbury distributes antibiotics to staff and students after meningitis cases detected, marking a worrying resurgence of the disease.

health

Neurowellness 2026: The Science of Regulating Your Nervous System

Neurowellness is the #1 wellness trend of 2026. Vagus nerve stimulation, breathwork, neurotech devices — the science of nervous system regulation explained.

health

CRISPR Cures Sickle Cell in 2026 — But Costs $2M Per Patient

Casgevy achieves near-miraculous results for sickle cell and beta-thalassemia in 2026 at $2M+ per treatment. Here is who qualifies, who pays, and what comes next.

health